Real Life Effectiveness in Patients With Not Optimally Controlled Asthma

Real Life Effectiveness in Patients With Not Optimally Controlled Asthma: Symbicort SMART, or Other ICS/LABA With as Needed SABA

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01647646

Enrollment

200

Registered

2012-07-23

Start date

2009-03-31

Completion date

2012-03-31

Last updated

2012-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

asthma, SMART, fixed dose

Brief summary

In real life, the investigators will be using different strategies including SMART therapy or other ICS/LABA (medium and high dose) therapy and measure the efficacy for asthma control.

Detailed description

1. All not-well controlled asthma patients would include the study. 2. We will compare three ways of asthma control including SMART, fixed doses with regular doses and fixed doses with higher doses 3. We will evaluate the efficacy/safety for these not-well controlled patients.

Interventions

DRUGSeretide

Using Symbicort and Seretide for asthma control measurements Compared with efficacy and safety

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* asthma not well control

Exclusion criteria

* COPD

Design outcomes

Primary

Measure	Time frame	Description
the percentage of asthma total and well control	one year	F/U clinical asthma control status and percentage of Acute exacerbation

Secondary

Measure	Time frame
percentage of asthma acute exacerbation	one year

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026